Betina Bitsch Trabjerg

Betina Bitsch Trabjerg

Auto-generated profile, based on publicly available information

Betina Bitsch Trabjerg

National Centre for Register-based Research, Department of Public Health, Aarhus University, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
BTBetina B. Trabjerg
Betina B. Trabjerg
FGFleur C. Garton
Fleur C. Garton
WRWouter van Rheenen
Wouter van Rheenen
FFFang Fang
Fang Fang
RHRobert D. Henderson
Robert D. Henderson
NWNaomi R. Wray
Naomi R. Wray
Objective To investigate the genetic contribution to amyotrophic lateral sclerosis (ALS) and the phenotypic and genetic associations between ALS and psychiatric and cardiovascular disorders (CVD) we used the national registry data from Denmark linked to first-degree relatives to estimate heritability and cross-trait parameters. Methods ALS cases and 100 sex and birth-matched controls per case from the Danish Civil Registration System were linked to their records in the Danish National Patient Registry. Cases and controls were compared for (1) risk of ALS in first-degree relatives, used to estimate heritability, (2) comorbidity with psychiatric disorders and CVD, and (3) risk of psychiatric disorders and CVD in first-degree relatives. Results 5,808 ALS cases and 580,800 controls were identified. Fifteen percent of cases and controls could be linked to both parents and full siblings, whereas 70% could be linked to children. (1) We estimated the heritability of ALS to be 0.43 (95% CI, 0.34–0.53). (2) We found increased rates of diagnosis of mental disorders (risk ratio = 1.18; 95% CI, 1.09–1.29) and CVD in those later diagnosed with ALS. (3) In first-degree relatives of those with ALS, we found increased rate of schizophrenia (1.17; 95% CI, 0.96–1.42), but no evidence for increased risk CVD. Conclusions Heritability of ALS is lower than commonly reported. There is likely a genetic relationship between ALS and schizophrenia, and a nongenetic relationship between ALS and CVD.

5 July 2022 in Epilepsia
Verified
Journal Article
Open access
JCJakob Christensen
Jakob Christensen
BTBetina B. Trabjerg
Betina B. Trabjerg
JDJulie Werenberg Dreier
Julie Werenberg Dreier
Objective: The US Food and Drug Administration recently issued a warning against the use of the antiseizure medication lamotrigine in people at risk of cardiac rhythm and conduction abnormalities. This study assessed the risk of cardiac morbidity and mortality in new users of lamotrigine.Methods: In a Danish population‐based cohort study, we followed cohort members aged ≥15 years for the first 2 years after they initiated lamotrigine therapy. The main outcomes were cardiac conduction disorders in people without pre‐existing cardiac morbidity and all‐cause mortality in people with pre‐existing cardiac morbidity. Cox proportional hazards models provided hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for comparison of the risk in current versus past users of lamotrigine.Results: There were 91 949 (36 618 males [39.8%]) new users of lamotrigine (median age = 45.7 years, interquartile range = 32.0–60.2 years). Among users without pre‐existing cardiac disease (n = 86 769), 194 (.23%) developed a cardiac conduction disorder. Comparison of the risk in current and past lamotrigine treatment periods yielded an adjusted HR of new onset cardiac conduction disorder of 1.03 (95% CI = .76–1.40). Among users with pre‐existing cardiac disease (n = 5180), 1150 (22.2%) died. Comparison of the risk in current and past lamotrigine treatment periods yielded an adjusted HR for all cause‐mortality of 1.05 (95% CI = .93–1.19).Significance: In this large population‐based study, lamotrigine use was associated neither with a risk of cardiac conduction disorders in people without pre‐existing cardiac morbidity nor with all‐cause mortality in people with pre‐existing cardiac morbidity.

6 December 2016 in Schizophrenia Research
Verified
Journal Article
Closed access
PDF file
TLThomas M. Laursen
Thomas M. Laursen
BTBetina B. Trabjerg
Betina B. Trabjerg
OMOle Mors
Ole Mors
ABAnders D. Børglum
Anders D. Børglum
DHDavid M. Hougaard
David M. Hougaard
EAEsben Agerbo
Esben Agerbo

2 November 2021 in JAMA
Verified
Journal Article
Open access
PDF file
JCJakob Christensen
Jakob Christensen
BTBetina B. Trabjerg
Betina B. Trabjerg
YSYuelian Sun
Yuelian Sun
JDJulie Werenberg Dreier
Julie Werenberg Dreier
Quiz Ref ID The prevalence of depression and anxiety in females peaks during childbearing years.1,2 Accordingly, antidepressants are widely used for women of fertile age, including pregnant women. Use of antidepressants in pregnancy varies between countries and within regions, with estimates ranging between 2% and 10%.3-6 Quiz Ref ID Antidepressants may be discontinued during pregnancy out of concern for the unborn child,7 leaving underlying maternal psychiatric conditions untreated.3,4,8 Given the serious health implications of psychiatric disorders, particularly around the time of delivery, discontinuation of relevant, well-indicated treatment with antidepressants is not a trivial issue. Thus, it is essential to determine whether antidepressant treatment during pregnancy is safe not only with regard to the risk of congenital malformations,9 but also with regard to cognitive10 and neuropsychiatric development.11,12 Numerous studies have assessed outcomes associated with prenatal exposure to antidepressants13; however, this is inherently difficult because randomized assessment of drug effects in pregnancy is not possible. Studies are, therefore, observational in nature and subject to varying degrees of confounding from, eg, underlying maternal psychiatric disorders.10-12,14 Moreover, only few long-term studies have been conducted on prenatal exposure to antidepressants, especially studies focusing on cognitive outcome and school performance in the offspring.13

28 September 2021 in Epilepsia
Verified
Journal Article
Closed access
PDF file
JCJakob Christensen
Jakob Christensen
BTBetina B. Trabjerg
Betina B. Trabjerg
YSYuelian Sun
Yuelian Sun
NGNils Erik Gilhus
Nils Erik Gilhus
MBMarte-Helene Bjørk
Marte-Helene Bjørk
JDJulie Werenberg Dreier
Julie Werenberg Dreier

25 September 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FGFleur C Garton
Fleur C Garton
BTBetina B Trabjerg
Betina B Trabjerg
NWNaomi R Wray
Naomi R Wray
EAEsben Agerbo
Esben Agerbo